Acumen Pharmaceuticals, Inc. (ABOS)
NASDAQ: ABOS · Real-Time Price · USD
2.460
-0.060 (-2.38%)
Apr 28, 2026, 4:00 PM EDT - Market closed

Acumen Pharmaceuticals Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 2020 - 2019
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 2020 - 2019
Net Income
-121.34-102.33-52.37-42.86-100.61
Upgrade
Depreciation & Amortization
0.180.180.180.170
Upgrade
Asset Writedown & Restructuring Costs
--0.74--
Upgrade
Loss (Gain) From Sale of Investments
-0.87-5.11-3.130.490.16
Upgrade
Stock-Based Compensation
9.859.646.153.060.92
Upgrade
Other Operating Activities
1.75-0.241.51-81.27
Upgrade
Change in Accounts Payable
-5.094.27-0.260.550.56
Upgrade
Change in Other Net Operating Assets
-0.037.384.133.43-0.26
Upgrade
Operating Cash Flow
-115.54-86.22-43.06-35.15-17.96
Upgrade
Capital Expenditures
-0.09-0.02-0.02-0.16-0.04
Upgrade
Sale of Property, Plant & Equipment
--0--
Upgrade
Investment in Securities
134.0248.04-171.6539.35-104.08
Upgrade
Investing Cash Flow
133.9348.03-171.6739.19-104.12
Upgrade
Long-Term Debt Issued
--30--
Upgrade
Long-Term Debt Repaid
--0.74---
Upgrade
Net Debt Issued (Repaid)
--0.7430--
Upgrade
Issuance of Common Stock
0.047.94122.233.91169.19
Upgrade
Repurchase of Common Stock
-0.07-0.04---
Upgrade
Other Financing Activities
--0.23-0.48--
Upgrade
Financing Cash Flow
-0.036.93151.753.91200.47
Upgrade
Net Cash Flow
18.36-31.26-62.987.9478.39
Upgrade
Free Cash Flow
-115.63-86.23-43.09-35.31-18
Upgrade
Free Cash Flow Per Share
-1.91-1.44-0.89-0.87-0.90
Upgrade
Cash Interest Paid
2.942.970.17--
Upgrade
Levered Free Cash Flow
-75.11-52.29-28.24-20.94-16.35
Upgrade
Unlevered Free Cash Flow
-72.47-49.75-27.87-20.94-16.35
Upgrade
Change in Working Capital
-5.1211.653.873.990.3
Upgrade
Source: S&P Capital IQ. Standard template. Financial Sources.